CNS Openings?

Quote






Truly hoping for a genuine response before I make a big career move.

Should one even consider a highbred position at Sunovion?

please someone give me some good insights and genuine response
 












Correct depends on where you are coming from. Not much time left on Latuda patent. Been here 8 years and it’s been great. We have another drug in the pipeline that has potential to be a blockbuster however timing of approval and positive phase 3 trials will be the key. Also if it’s calling on neuro it’s great to get neuro experience on the resume!
 


















anonymous said:
Correct depends on where you are coming from. Not much time left on Latuda patent. Been here 8 years and it’s been great. We have another drug in the pipeline that has potential to be a blockbuster however timing of approval and positive phase 3 trials will be the key. Also if it’s calling on neuro it’s great to get neuro experience on the resume!
Click to expand...

SEP-856 has good potential but if you look at publicly available information on clinical trials.gov, the patient recruitment is not great and way office mark, likely due to Covid.

What should have been a small gap between the Latuda patent and SEP856 approval is now likely more sizable.
 


















anonymous said:
SEP-856 has good potential but if you look at publicly available information on clinical trials.gov, the patient recruitment is not great and way office mark, likely due to Covid.

What should have been a small gap between the Latuda patent and SEP856 approval is now likely more sizable.
Click to expand...

This drug may not even be approved, and 4199 DEF won’t be approved (in case you haven’t heard). Enjoy an overactive bladder co-promote, cause that’s all that’s gonna be in the bag of the few that are left after the massive layoff. Japan already has plans…
 






anonymous said:
This drug may not even be approved, and 4199 DEF won’t be approved (in case you haven’t heard). Enjoy an overactive bladder co-promote, cause that’s all that’s gonna be in the bag of the few that are left after the massive layoff. Japan already has plans…
Click to expand...

You may be right with 4199, but time will tell. 856 however is a near slam dunk. The issue with 856 is IF they'll explore other indications and WHEN.

DSP and Sunovion Finance do not want to spend money on clinical trials, and do not understand how this industry works. They fundamentally do not understand long-term capital planning in this industry and what it means long-term if you don't invest in a pipeline.

Finance would rather blow smoke and shovel cash up to DSP, get fat bonuses for themselves than to have the difficult conversation with DSP about investing into the pipeline and clinical trials. Here we are today, with all these looming problems, and the very people who refuse to spend money on trials are completely dumbfounded why the pipeline is thin, has big gaps between products and only go into very low-risk safe indications that don't bring in the revenue to sustain operations (i.e Kynmobi, Lonhaler, that failed ADHD/Binge Eating drug).
 












anonymous said:
You may be right with 4199, but time will tell. 856 however is a near slam dunk. The issue with 856 is IF they'll explore other indications and WHEN.

DSP and Sunovion Finance do not want to spend money on clinical trials, and do not understand how this industry works. They fundamentally do not understand long-term capital planning in this industry and what it means long-term if you don't invest in a pipeline.

Finance would rather blow smoke and shovel cash up to DSP, get fat bonuses for themselves than to have the difficult conversation with DSP about investing into the pipeline and clinical trials. Here we are today, with all these looming problems, and the very people who refuse to spend money on trials are completely dumbfounded why the pipeline is thin, has big gaps between products and only go into very low-risk safe indications that don't bring in the revenue to sustain operations (i.e Kynmobi, Lonhaler, that failed ADHD/Binge Eating drug).
Click to expand...

a real response thank you!
 






anonymous said:
You may be right with 4199, but time will tell. 856 however is a near slam dunk. The issue with 856 is IF they'll explore other indications and WHEN.

DSP and Sunovion Finance do not want to spend money on clinical trials, and do not understand how this industry works. They fundamentally do not understand long-term capital planning in this industry and what it means long-term if you don't invest in a pipeline.

Finance would rather blow smoke and shovel cash up to DSP, get fat bonuses for themselves than to have the difficult conversation with DSP about investing into the pipeline and clinical trials. Here we are today, with all these looming problems, and the very people who refuse to spend money on trials are completely dumbfounded why the pipeline is thin, has big gaps between products and only go into very low-risk safe indications that don't bring in the revenue to sustain operations (i.e Kynmobi, Lonhaler, that failed ADHD/Binge Eating drug).
Click to expand...

Yup, that’s what you’re being TOLD about 856. It’s what you’re not being told that’s the problem. Your fearless leaders have no issue whatsoever not being honest with you. I’m not going to argue, I’ll just put a reminder on my calendar to come back in a year and drop an “I warned you…” on this thread.
 












anonymous said:
Since they don’t tell us anything as usual, please share what happened w 4199?
Click to expand...

Its out there as public information, look at the press releases from last year and the DSP Earnings Report on the Investors page. Mixed bag phase 2 results but some good signs, and moving into Phase 3 soon.

DSP and Sunovion do a piss-poor job of telling the employees anything, it’s one of the worst internal communications teams I’ve seen. Look up the Quarterly Earnings Reports on the DSP investors page if you want information in the future
 






























Top Bottom
Back
Quote